Biohaven Ltd. (BHVN) - Total Assets
Based on the latest financial reports, Biohaven Ltd. (BHVN) holds total assets worth $466.41 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Biohaven Ltd. stock price for real-time trading data and today's change.
Biohaven Ltd. - Total Assets Trend (2017–2025)
This chart illustrates how Biohaven Ltd.'s total assets have evolved over time, based on quarterly financial data. Also see Biohaven Ltd. cash conversion from operations for how efficiently the company converts equity into cash flow.
Biohaven Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
Biohaven Ltd.'s total assets of $466.41 Million consist of 81.6% current assets and 18.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 50.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $18.40 Million | 4.1% |
| Goodwill | $1.39 Million | 0.3% |
Asset Composition Trend (2017–2025)
This chart illustrates how Biohaven Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BHVN net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biohaven Ltd.'s current assets represent 81.6% of total assets in 2025, a decrease from 93.0% in 2017.
- Cash Position: Cash and equivalents constituted 50.9% of total assets in 2025, down from 89.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 4.1% of total assets.
Biohaven Ltd. Competitors by Total Assets
Key competitors of Biohaven Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.38 Billion |
Biohaven Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.41 | 2.33 | 1.67 |
| Quick Ratio | 7.41 | 2.33 | 1.51 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $333.57 Million | $218.72 Million | $267.45 Million |
Biohaven Ltd. - Advanced Valuation Insights
This section examines the relationship between Biohaven Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.04 |
| Latest Market Cap to Assets Ratio | 4.62 |
| Asset Growth Rate (YoY) | -26.6% |
| Total Assets | $451.45 Million |
| Market Capitalization | $2.09 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Biohaven Ltd.'s assets at a significant premium (4.62x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Biohaven Ltd.'s assets decreased by 26.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biohaven Ltd. (2017–2025)
The table below shows the annual total assets of Biohaven Ltd. from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $451.45 Million | -26.61% |
| 2024-12-31 | $615.11 Million | +19.85% |
| 2023-12-31 | $513.21 Million | -22.45% |
| 2022-12-31 | $661.78 Million | +365.84% |
| 2021-12-31 | $142.06 Million | +27.41% |
| 2020-12-31 | $111.50 Million | -67.61% |
| 2019-12-31 | $344.26 Million | +18.71% |
| 2018-12-31 | $290.01 Million | +97.44% |
| 2017-12-31 | $146.89 Million | -- |
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase… Read more